pubmed-article:2560678 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:2560678 | lifeskim:mentions | umls-concept:C0025255 | lld:lifeskim |
pubmed-article:2560678 | lifeskim:mentions | umls-concept:C0018787 | lld:lifeskim |
pubmed-article:2560678 | lifeskim:mentions | umls-concept:C0006104 | lld:lifeskim |
pubmed-article:2560678 | lifeskim:mentions | umls-concept:C0004599 | lld:lifeskim |
pubmed-article:2560678 | lifeskim:mentions | umls-concept:C0028127 | lld:lifeskim |
pubmed-article:2560678 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
pubmed-article:2560678 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
pubmed-article:2560678 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
pubmed-article:2560678 | pubmed:issue | 12 | lld:pubmed |
pubmed-article:2560678 | pubmed:dateCreated | 1990-4-23 | lld:pubmed |
pubmed-article:2560678 | pubmed:abstractText | The effects of bacitracin were investigated on [3H]nitrendipine binding to rat brain and cardiac membranes in a low ionic strength (5 mM Tris-HCl) buffer. Bacitracin inhibited [3H]nitrendipine binding to rat brain and cardiac membranes with IC50 values of 400 +/- 100 and 4600 +/- 400 micrograms/mL, respectively. Scatchard analysis in brain membranes revealed that bacitracin inhibited [3H]nitrendipine binding primarily by reducing the Bmax but also by producing a small increase in the Kd. In brain membranes, Na+ (100 mM) and Ca2+ (2 mM) reduced the potency of bacitracin to inhibit [3H]nitrendipine binding by approximately sixfold with IC50 values of 2600 +/- 300 and 2100 +/- 400 micrograms/mL observed for bacitracin in the presence of 100 mM Na+ and 2 mM Ca2+, respectively. The EC50 values for the effects of Na+ and Ca2+ were 800 +/- 200 microM and 25 +/- 5 mM. K+, Mg2+, choline, and increasing the assay buffer of Tris-HCl to 50 mM also decreased the inhibition of [3H]nitrendipine binding by bacitracin. These results suggest that bacitracin specifically modulates [3H]nitrendipine binding in a cation-dependent manner and that brain and cardiac dihydropyridine binding sites are either biochemically different or exist in a different membrane environment. | lld:pubmed |
pubmed-article:2560678 | pubmed:language | eng | lld:pubmed |
pubmed-article:2560678 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2560678 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:2560678 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2560678 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2560678 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2560678 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2560678 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2560678 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:2560678 | pubmed:month | Dec | lld:pubmed |
pubmed-article:2560678 | pubmed:issn | 0008-4212 | lld:pubmed |
pubmed-article:2560678 | pubmed:author | pubmed-author:SmithJ DJD | lld:pubmed |
pubmed-article:2560678 | pubmed:author | pubmed-author:BolgerG TGT | lld:pubmed |
pubmed-article:2560678 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:2560678 | pubmed:volume | 67 | lld:pubmed |
pubmed-article:2560678 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:2560678 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:2560678 | pubmed:pagination | 1591-5 | lld:pubmed |
pubmed-article:2560678 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:2560678 | pubmed:meshHeading | pubmed-meshheading:2560678-... | lld:pubmed |
pubmed-article:2560678 | pubmed:meshHeading | pubmed-meshheading:2560678-... | lld:pubmed |
pubmed-article:2560678 | pubmed:meshHeading | pubmed-meshheading:2560678-... | lld:pubmed |
pubmed-article:2560678 | pubmed:meshHeading | pubmed-meshheading:2560678-... | lld:pubmed |
pubmed-article:2560678 | pubmed:meshHeading | pubmed-meshheading:2560678-... | lld:pubmed |
pubmed-article:2560678 | pubmed:meshHeading | pubmed-meshheading:2560678-... | lld:pubmed |
pubmed-article:2560678 | pubmed:meshHeading | pubmed-meshheading:2560678-... | lld:pubmed |
pubmed-article:2560678 | pubmed:meshHeading | pubmed-meshheading:2560678-... | lld:pubmed |
pubmed-article:2560678 | pubmed:meshHeading | pubmed-meshheading:2560678-... | lld:pubmed |
pubmed-article:2560678 | pubmed:meshHeading | pubmed-meshheading:2560678-... | lld:pubmed |
pubmed-article:2560678 | pubmed:meshHeading | pubmed-meshheading:2560678-... | lld:pubmed |
pubmed-article:2560678 | pubmed:meshHeading | pubmed-meshheading:2560678-... | lld:pubmed |
pubmed-article:2560678 | pubmed:meshHeading | pubmed-meshheading:2560678-... | lld:pubmed |
pubmed-article:2560678 | pubmed:year | 1989 | lld:pubmed |
pubmed-article:2560678 | pubmed:articleTitle | Selective inhibition of [3H]nitrendipine binding to brain and cardiac membranes by bacitracin. | lld:pubmed |
pubmed-article:2560678 | pubmed:affiliation | Memorial University of Newfoundland, St. John's, Canada. | lld:pubmed |
pubmed-article:2560678 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:2560678 | pubmed:publicationType | In Vitro | lld:pubmed |
pubmed-article:2560678 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2560678 | lld:pubmed |